Incidental Papillary Thyroid Carcinoma: Clinical and Histopathological Comparison between Graves’ disease and Euthyroid Nodular Goiter

Zainab M. Jawad  Alkhirsan; May Azher  Gheni

doi:10.51699/cajmns.v7i2.3125

Authors

Zainab M. Jawad Alkhirsan Faculty of Medicine, Jabir Ibn Hayyan University for Medical and Pharmaceutical Sciences, Ministry of Higher Education and Scientific Research, Al-Najaf, Iraq
May Azher Gheni Neurosurgery Teaching Hospital, Baghdad Al-Rusafa Health Directorate, Iraqi Ministry of Health, Baghdad, Iraq

DOI:

https://doi.org/10.51699/cajmns.v7i2.3125

Keywords:

Papillary Thyroid Carcinoma, Histopathological Outcomes, Post – Operative Complications

Abstract

Incidental papillary thyroid carcinoma (IPTC) is commonly to be detected during thyroidectomy in the case of benign thyroid lesions. Two of the common underlying pathologies are the disease known as Graves' disease (GD) and euthyroid nodular goiter (ENG). This purpose study aimed to determine the incidence, histopathology, and clinical outcome of IPTC in patients undergoing thyroidectomy with GD compared to those having ENG. The study based on the approach methodology was a cross-sectional study about 117 patients who had undergone a thyroidectomy, that is, 53 patients with Graves' disease and 64 patients with euthyroid nodular goiter. The groups were compared in terms of clinical, demographic, and histopathological data. Assessed parameters were tumor size, multifocality, extrathyroidal extension (ETE), tumor lymph node metastasis (LNM), histological variants, preoperative TSH level, post-operative complications, and recurrence rates, with a mean follow-up of 12 months between January 2024 and January 2025. In addition, incidental papillary thyroid carcinoma (IPTC) was found in 37.7% of the patients with Graves' disease (20/53) and 25.0% of the patients with ENG (16/64). Multifocality (30.0% vs. 18.8%), ETE (25.0% vs. 12.5%), and LNM (40.0% vs. 18.8%), which were not statistically significant (p-values 0.45, 0.29, and 0.10, respectively), exhibited numerically higher rates in GD-associated IPTC. It suppressed preoperative TSH (below 0.1 mIU/L) in 67.9% of GD patients and in 3.1% of ENG patients. There were similar rates of complications in the postoperative period, such as hypocalcemia and nerve injury. In conclusion, incidental papillary thyroid carcinoma (IPTC) is more common in Graves' disease patients than in patients with euthyroid nodular goiter. Even though GD-associated IPTC is more trended towards more aggressive histopathological features, nevertheless, both groups had shown very good disease-free survival and similar results of surgery. In addition, the results indicate that although GD could be linked to increased frequency of IPTC, clinical handling of IPTC and prognosis in GD and ENG patients are positive and comparable.

References

T. J. Smith and L. Hegedus, “Graves’ disease,” N. Engl. J. Med., vol. 375, pp. 1552–1565, 2016.

C. M. Girgis, B. L. Champion, and J. R. Wall, “Current concepts in Graves’ disease,” Ther. Adv. Endocrinol. Metab., vol. 2, pp. 135–144, 2011.

N. Kustrimović, D. Gallo, E. Piantanida et al., “Regulatory T cells in the pathogenesis of Graves’ disease,” Int. J. Mol. Sci., vol. 24, 16432, 2023.

M. P. Vanderpump, W. M. Tunbridge, J. M. French et al., “The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey,” Clin. Endocrinol., vol. 43, pp. 55–68, 1995.

B. Song, Z. Lin, C. Feng et al., “Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis,” Front. Endocrinol., vol. 14, 1252389, 2023.

C. Cappelli, M. Braga, E. D. Martino et al., “Outcome of patients surgically treated for various forms of hyperthyroidism with differentiated thyroid cancer,” Surg. Today, vol. 36, pp. 125–130, 2006.

S. Wei, Z. W. Baloch, and V. A. LiVolsi, “Thyroid carcinoma in patients with Graves’ disease: an institutional experience,” Endocr. Pathol., vol. 26, pp. 48–53, 2015.

R. S. Bahn, H. B. Burch, D. S. Cooper et al., “Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association,” Thyroid, vol. 21, pp. 593–646, 2011.

D. S. Ross, H. B. Burch, D. S. Cooper et al., “2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis,” Thyroid, vol. 26, pp. 1343–1421, 2016, doi:10.1089/thy.2016.0229.

K. Pazaitou-Panayiotou, P. Perros, M. Boudina et al., “Mortality from thyroid cancer in patients with hyperthyroidism,” Eur. J. Endocrinol., vol. 159, pp. 799–803, 2008.

G. Boutzios, I. Vasileiadis, E. Zapanti et al., “Higher incidence of tall cell variant of papillary thyroid carcinoma in Graves’ disease,” Thyroid, vol. 24, pp. 347–354, 2014.

S. Iwama, A. Ikezaki, N. Kikuoka et al., “Association of HLA-DR, -DQ genotype and CTLA-4 gene polymorphism with Graves’ disease in Japanese children,” Horm. Res., vol. 63, pp. 55–60, 2005.

C. Gopinath, H. Crow, S. Panthi et al., “Characteristics, staging, and outcomes of differentiated thyroid cancer in patients with and without Graves’ disease,” J. Clin. Transl. Endocrinol., vol. 33, 100321, 2023.

G. Pellegriti, C. Mannarino, M. Russo et al., “Increased mortality in patients with differentiated thyroid cancer associated with Graves' disease,” J. Clin. Endocrinol. Metab., vol. 98, pp. 1014–1021, 2013.

H. Kim, H. Kwon, and B. I. Moon, “Predictors of recurrence in patients with papillary thyroid carcinoma: Does male sex matter?” Cancers, vol. 14, 1896, 2022.

Y. E. Nikiforov, R. R. Seethala, G. Tallini et al., “Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma,” JAMA Oncol., vol. 2, pp. 1023–1029, 2016.

B. R. Haugen, E. K. Alexander, K. C. Bible et al., “2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer,” Thyroid, vol. 26, pp. 1–133, 2016.

Y. Yuan, X. Li, W. Ni et al., “Proangiogenic effect of thyrotropin receptor-stimulating antibody in human umbilical vein endothelial cells,” Endocrine, vol. 87, pp. 697–706, 2024.

S. Rajabi, M. H. Dehghan, R. Dastmalchi et al., “The roles and role-players in thyroid cancer angiogenesis,” Endocr. J., vol. 66, pp. 277–293, 2019.

K. Pazaitou-Panayiotou, K. Michalakis, and R. Paschke, “Thyroid cancer in patients with hyperthyroidism,” Horm. Metab. Res., vol. 44, pp. 255–262, 2012.